GlassScriptPhysician profile
Scott A Phillips
NPI 1669722393
$2,914.39
in general payments reported to CMS, 2019-2025
25 companies · $883 in 2025
The $883 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $292 · 2022: $363 · 2023: $706 · 2024: $671 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.67 | 2021-2025 | |
| Amgen INC. | $519.16 | 2021-2025 | Tavneos, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $172.08 | 2022-2025 | Saphnelo |
| Bioventus LLC | $150.98 | 2023-2025 | Durolane, Durolane, Xcell |
| Bsn Medical INC | $144.04 | 2025 | |
| Novartis Pharmaceuticals Corporation | $140.93 | 2023-2025 | |
| Glaxosmithkline, LLC. | $119.35 | 2022-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $114.95 | 2023-2025 | Idacio |
| Janssen Biotech, INC. | $113.65 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Horizon Therapeutics Plc | $82.85 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $77.12 | 2021-2024 | Taltz, Zepbound |
| Genentech USA, INC. | $76.26 | 2021-2025 | Gazyva, Actemra, Rituxan |
| Ucb, INC. | $59.71 | 2022-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $57.78 | 2023-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $57.73 | 2021-2024 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.07 | 2022-2025 | |
| Organon LLC | $51.59 | 2022-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $49.95 | 2023-2025 | Purified Cortrophin Gel |
| Pacira Pharmaceuticals Incorporated | $49.34 | 2023 | Zilretta, Iovera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.44 | 2023-2024 | |
| Sandoz INC. | $38.13 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $29.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $22.99 | 2025 | |
| Merck Sharp & Dohme LLC | $17.78 | 2021 | |
| Depuy Synthes Sales INC. | $15.23 | 2023 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.